Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 39

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  Lydium-KLP
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
The studies were done in 9 farms on 187 cows affected with a subclinical bacterial mastitis (260 quarters), sub- clinical aseptic mastitis (73 quarters) and latent infections (23 quarters). In the treatment, Lydium-KLP was applied intravenously once at a dose of 0.015-0.020 mg of lysozyme dimmer/kg of body weight. Control examinations carried out on 7, 14, 21 and 28 days after the treatment showed a high effectiveness of lysozyme dimmer in the treatment of subclinical mastitis. From 38.9% to 76.3% infected quarters (average 64.5 %) werer cured in particular farms. Effectiveness of the therapy used was high in cases when one quarter of an udder was affected and a somatic cell count did not exceed 3 million/ml of milk. The cure rate was the following: 50% for quarters infected with S. aureus, 57.9% for quarters infected with S. agalactiae and 88.1% for quarters infected with other microorganisms.
The objective of clinical observations was to evaluate Lydium-KLP (NIKA) usefulness in treatment of some tumors in pets. The active ingredient of Lydium-KLP is the lysozyme dimer that affects various mechanisms of cellular and humoral defense. The research concerned a group of 118 dogs and 18 cats with neoplastic changes that differed in progress and malignancy level. The animals were divided into three groups: a control group and two experimental groups. The control group (41 animals) was treated with the conventional method composed of surgical procedure (removing tumors and other changed tissue) and applications of protective and palliative drugs. The first experimental group consisting of 37 dogs and cats was treated with surgical procedure and then with injections of Lydium-KLP (at least 8 times) in doses of 20-40 pg/kg b.w. i.m. or s.c. (combined method). The second experimental group was made up of 40 dogs and cats. In this case the conservative method (only Lydium-KLP injections) was implemented. The effectiveness was checked for the period of 6-24 months after the therapy had been carried out. The combined method appeared to be the most effective (67.6% of recovery) followed by the conventional (61.0%) and conservative one (45%). Lysozyme dimer injections led to quicker recoveries of surgically treated animals. As a consequence of the combined therapy there were fewer recidivations, metastasises, and postoperative complications, as compared with the conventional treatment. The conservative therapy resulted in progress termination or even regression of tumors like adenocarcinoma, adenofibroma, seminoma and papilloma. The results of these obervations indicate the validity of continuing research on the application of lysozyme dimer (Lydium-KLP) in treatment of animals affected by neoplasms.
Field trials were carried out on 56 sick sows at private farms. The animals were affected with metritis-mastitis- -agalactiae syndrome or metritis and toxaemia caused by dystocia or retained placenta. Lydium-KLP (NIKA Health Products) was injected intravenously or intramuscularly as: 1) a self-dependent drug once or twice every 24 hours; 2) together with oxytocin; 3) in the form of intramuscular injection of the drug together with antibiotics. The single dose of Lydium-KLP was 0.02 mg/kg of body weight (lysozyme dimer as the active ingredient). The treatment of perinatal disorders with Lydium-KLP resulted in 83.9% recovery of sows. The effectiveness of MMA treatment was more than 90%. It seems that effective therapy should be based on Lydium-KLP administration; antibiotics ought to be applied in case of unsatisfactory findings within 24 hours.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.